AMADO RAFAEL G ET AL: "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 26, no. 10, 1 April 2008 (2008-04-01) , pages 1626-1634, XP009104317, ISSN: 0732-183X (B1)

BENVENUTI SILVIA ET AL: "Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies", 20070315, 15 March 2007 (2007-03-15), XP002491315, (B1)

CARAGLIA MICHELE ET AL: "EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.", RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY JUN 2006, vol. 1, no. 2, June 2006 (2006-06), pages 209-222, XP009104857, ISSN: 1574-8928 (B1)

CHUA YU JO ET AL: "Panitumumab", DRUGS OF TODAY, vol. 42, no. 11, November 2006 (2006-11), pages 711-719, XP002493245, ISSN: 1699-3993 (B1)

CLAUDIA AUGELLO ET AL: "TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 207, no. 3, 1 June 2006 (2006-06-01), pages 654-659, XP055051872, ISSN: 0021-9541, DOI: 10.1002/jcp.20601 (B1)

WO-A2-2007/011702 (B1)

FRIDAY ET AL: "K-ras as a target for cancer therapy", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1756, no. 2, 25 November 2005 (2005-11-25), pages 127-144, XP005204727, ISSN: 0304-419X (B1)

LIÈVRE ASTRID ET AL: "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.", CANCER RESEARCH 15 APR 2006, vol. 66, no. 8, 15 April 2006 (2006-04-15) , pages 3992-3995, XP002400937, ISSN: 0008-5472 (B1)

PAO W ET AL: "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib", PLOS MEDICINE 2005 US, vol. 2, no. 1, 2005, pages 0057-0061, XP002400935, (B1)

WO-A-2007/001868 (B1)

EBERHARD D A ET AL: "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 23, no. 25, 1 September 2004 (2004-09-01), pages 5900-5909, XP002400936, ISSN: 0732-183X (B1)